A carregar...
Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%–5% of all NSCLC patients. ALK+ NSCLC cells re...
Na minha lista:
| Publicado no: | Clin Epidemiol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4242069/ https://ncbi.nlm.nih.gov/pubmed/25429239 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CLEP.S69718 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|